1010 Sherbrooke Street West
Embedded in its novel mechanism of action, Diazon’s new generation onco-therapeutic DZ-2384 targets a proven therapeutic pathway in oncology, but one whose potential in modern cancer therapy has been severely restricted due to unacceptable toxicities. DZ-2384 overcomes this restriction by modulating microtubule structure and dynamics in a distinct way, delivering potent anti-tumor efficacy with an unusually superior safety profile, including lack of neurotoxicity in preclinical models – qualities that are widely sought by clinicians. In addition to replacing the current drugs that target microtubules, Diazon believes that DZ-2384 has the potential to safely combine with targeted therapeutics, including immunotherapies.
Founders: Patrick Harran, Gordon Shore and Anne Roulston
CFO: Michael Dixon
CSO: Gordon Shore
CDO: Louise Proulx